Minerva Neurosciences, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are included where disclosed. Minerva is a clinical-stage CNS biopharmaceutical company with no approved products and no product revenue.
Business context and pipeline
- MIN-101: Schizophrenia, particularly negative symptoms. The company reported positive Phase IIb results and planned to seek FDA and EMA input on pivotal trials.
- MIN-117: Major depressive disorder (MDD). Phase IIa was designed for signal detection, not statistical proof; U.S. trials were expected to begin in late 2017.
- MIN-202: Insomnia and MDD, co-developed with Janssen. Minerva holds commercialization rights in its European territory and shares development costs.
- MIN-301: Parkinson’s disease. Preclinical development continued; a Phase I study was anticipated after preparation for an IND or IMPD filing.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $20.4 million | $18.5 million |
| General and administrative expense | $9.8 million | $7.6 million |
| Total operating expenses / operating loss | $30.2 million | $26.1 million |
| Net loss | $31.0 million | $27.1 million |
| Basic and diluted loss per share | $0.99 | $1.16 |
| Net cash used in operating activities | $25.7 million | $24.3 million |
Margins are not meaningful because the company had no revenue. R&D expense increased mainly due to MIN-202 Phase II preparation and higher stock-based compensation, partly offset by completion of the MIN-101 Phase IIb trial. G&A rose mainly with personnel, professional fees and stock-based compensation. The 2015-to-2016 decrease in loss per share reflects a higher weighted-average share count, despite the larger net loss.
- Liquidity: At year-end, cash and cash equivalents were $83.0 million; there were no marketable securities. Total current assets were $83.9 million, total current liabilities $9.7 million, and total assets $132.9 million.
- Debt: Term A loans had $8.43 million principal outstanding at year-end, due by August 2018, at a fixed 7.05% rate. Balance-sheet notes payable, including current and noncurrent portions, were $8.69 million. The debt is secured by substantially all assets other than intellectual property; the company reported compliance with loan covenants.
- Cash generation and financing: 2016 financing cash flow was $76.6 million, including $53.7 million net proceeds from a June public offering and $23.4 million from warrant exercises. Cash increased by $68.7 million during the year.
- Share count: 35.0 million common shares were outstanding at year-end 2016; 35.29 million were outstanding as of March 10, 2017.
Fourth-quarter 2016 revenue was $0, operating loss was $9.2 million, net loss was $9.4 million and loss per share was $0.27. The comparable fourth-quarter 2015 net loss was $8.4 million, or $0.34 per share.
Material developments, outlook and risks
- MIN-101’s Phase IIb trial met its primary endpoint: both 32 mg and 64 mg doses improved negative symptoms versus placebo. The filing reports QTcF-related discontinuations for two patients receiving MIN-101 in the core trial, both at 64 mg; cardiac monitoring and follow-up studies were ongoing. Phase III initiation was expected in the second half of 2017, subject to regulatory discussions.
- MIN-117 Phase IIa showed dose-dependent effects versus placebo, but the 84-patient study was not powered for statistical significance. The company described U.S. studies as planned for late 2017.
- MIN-202 insomnia Phase IIa reported statistically significant improvement in sleep-efficiency measures; the small MDD Phase Ib study provided preliminary findings. Neither constitutes pivotal evidence. Janssen and Minerva passed a development decision point in July 2016; Minerva reported up to $15.3 million of additional expected payments for specified Phase II work. Contractual obligations tabled at year-end included $15.5 million for the co-development agreement, all due within one year.
- Management expected year-end cash to fund operations into the second quarter of 2018 under its current plan, while stating cash was sufficient for at least 12 months after the financial statements were issued. The company expects continuing losses and negative operating cash flow and says additional capital will be needed for later-stage trials; financing may dilute shareholders or be unavailable on acceptable terms.
- Principal risks include clinical and regulatory failure or delay, safety issues, reliance on CROs and contract manufacturers, limited operating and commercialization experience, dependence on MTPC and Janssen agreements, competition, patent duration/protection, reimbursement uncertainty, and possible limits on use of tax-loss carryforwards. MIN-101/MIN-117 cardiac or QT/QTc concerns and the company’s small workforce are also relevant.
- No material legal proceedings were reported. Goodwill and in-process R&D were not impaired in 2016. The independent auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. The auditor did not attest to internal-control effectiveness.
Key facts for investors to verify
- Progress and regulatory feedback on MIN-101 Phase III design, timing, and QTcF safety monitoring.
- Whether MIN-117’s later, adequately powered trials reproduce the exploratory Phase IIa signal.
- MIN-202 Phase II outcomes, remaining development-cost exposure, and Janssen’s continued participation.
- Actual cash burn and financing runway relative to the stated Q2 2018 outlook, including debt repayments and potential dilution.
- Patent protection, licensing obligations, and any impairment or changes in commercial prospects for the pipeline assets.